Ranitidine is a competitive, reversible inhibitor of the action of histamine at histamine H2-receptors, including receptors on gastric cells, with a minimal effect on H1-receptors. It is one of the drugs of choice for the treatment of active duodenal ulcers, gastric ulcers, Zollinger-Ellison syndrome, gastroesophageal reflux disease, and erosive esophagitis. The indicated oral dosage of Ranitidine is 150 mg, twice daily, or 300 mg once daily. In the treatment of endoscopically diagnosed erosive esophagitis, the dosage is 150 mg Ranitidine four times a day.\[[@ref1][@ref2]\] It has been found that the conventional dose of 150 mg can inhibit gastric acid secretion for up to five hours, but not up to 10 hours, and at the same time, an alternative dose of 300 mg leads to fluctuations in the plasma levels. Taking this into consideration, a sustained release dosage form of Ranitidine hydrochloride (R-HCl) will be very useful.\[[@ref3]\] The drug has a short biological half-life of approximately two to three hours, an absolute bioavailability of only 50%, and it is absorbed only in the initial part of the small intestine.\[[@ref4]--[@ref6]\] Colonic metabolism of Ranitidine is also partly responsible for the poor bioavailability of Ranitidine from the colon.\[[@ref7]\] A gastroretentive drug delivery system that can be retained in the stomach and increases the local delivery of R-HCl will also be very useful. Local delivery also increases bioavailability of the stomach wall receptor site and increases the efficacy of drugs, to reduce acid secretion.\[[@ref8]\] There are a number of approaches that can be used to prolong gastric retention time, such as, swelling and expanding systems, polymeric bioadhesive systems, modified-shape systems, high-density systems, and other delayed gastric emptying devices.\[[@ref9][@ref10]\]

Hydrogels are cross-linked hydrophilic polymers with a network structure. They are able to imbibe large amounts of water and are water insoluble.\[[@ref11]--[@ref13]\] For pharmaceutical applications, they are unique carriers for controlled drug delivery; release control can be governed by both swelling and biodegrading properties.\[[@ref14]--[@ref16]\] Owing to their high water affinity and biocompatibility, hydrogels based on poly (acrylic acid) and its derivatives,\[[@ref17][@ref18]\] Chitosan,\[[@ref19]\] alginate,\[[@ref20]\] and collagen\[[@ref21]\] have attracted attention. However, these nonporous hydrogels swell slowly and exhibit low loading capacities,\[[@ref22][@ref23]\] which restrict their use in effective drug delivery. A new generation of hydrogel, Superporous Hydrogel (SPH), which absorbs water very rapidly and swells to equilibrium size in a short period of time, has been developed.\[[@ref24]--[@ref28]\] SPH synthesis involves copolymerization / cross-linking of co-monomers using multifunctional co-monomer, which acts as cross-linking agent. Chemical initiator initiates the polymerization reaction. Gas blowing techniques are used to synthesize SPHs. The commonly used foaming agents are inorganic carbonates such as sodium carbonate and sodium bicarbonates. The second method involves cross-linking of linear polymers by irradiation or by chemical compounds.\[[@ref29]\] Several important properties of SPH, such as fast swelling, large swelling ratio, and surface slipperiness, make it an excellent candidate material to develop gastric retention devices.\[[@ref30]\] On account of the poor mechanical strength of SPHs, they are difficult to handle without breaking.\[[@ref31]\] Superporous Hydrogel Composites (SPHCs), as the second generation of SPHs, possess improved mechanical properties over SPHs, with composite agents such as, Chitosan,\[[@ref32][@ref33]\] Ac-Di-Sol,\[[@ref34][@ref35]\] and Carbopol.\[[@ref36]\]

The objectives of the investigation were: to synthesize SPHC containing Chitosan as a composite material to improve the characteristics of SPH and to prepare a drug delivery system based on it. Acrylic acid (AA) and Acrylamide (AM) were chosen as the base monomers for their high water affinity and fast copolymerization velocity,\[[@ref37]\] while Chitosan was selected as the second polymer component for its biocompatibility.\[[@ref38]\] A floating drug delivery system, which was less dense than gastric juice was described.\[[@ref39]\] Of late, research has been carried out using R-HCl as an effervescent-type of drug delivery system.\[[@ref40]\] Moreover, a new type of multiparticulate floating drug delivery system consisting of a highly porous carrier material (foam powder), a drug, and a polymer involving low density microparticles, has been proposed.\[[@ref41][@ref42]\] In the present investigation, preparation of a drug delivery system that delivers R-HCl in the stomach in a sustained manner, as a floating drug delivery system, using a low density SPHCs, has been attempted.

Materials and Methods {#sec1-1}
=====================

Materials {#sec2-1}
---------

R-HCl was a generous gift from Espee Formulation Pvt. Ltd., Rajkot, Gujarat, India. Chitosan was a generous gift from Mahtani Chitosan Pvt. Ltd., Veraval, Gujarat, India. AM was obtained from Burgoyne Burbidges and Co. Pvt. Ltd., Mumbai, India. AA, N,N'-Methylene-bis-acrylamide (BIS), Span 80, Ammonium Persulfate (APS), N,N,N',N'-Tetramethylethylenediamine (TEMED), Hydroxypropylmethyl cellulose (HPMC), Carbopol 934P, Ethyl cellulose (EC), and Sodium carboxymethyl cellulose (NaCMC) were purchased from SD Fine Chem Ltd., Mumbai, India. Double distilled water (DDW) was prepared in the laboratory. Simulated gastric fluid (SGF) with pH 1.2 was prepared in the laboratory by dissolving 2 g of sodium chloride, 3.2 g pepsin, and 6.8 ml of hydrochloric acid in DDW to produce 1 L. All other chemicals used were of analytical grade and were used as obtained.

SPHC synthesis {#sec2-2}
--------------

All ingredients except sodium bicarbonate were used as a solution in DDW. For the synthesis of SPHC of poly (AM-co-AA), the following substances were subsequently added into a test tube at 25°C: 300 *μ*l AM 50 %w/v; 200 *μ*l AA 50 %v/v; 70 *μ*l BIS 2.5 %w/v; 30 *μ*l span 80 10 %v/v; 25 *μ*l APS 20 %w/v;25 *μ*l TEMED 20 %v/v; 400 *μ*l Chitosan aqueous solution 6 %w/v, and 200 mg of sodium bicarbonate. The 400 *μ*l of Chitosan aqueous solution was selected based on the primary studies.\[[@ref33]\] SPH was prepared by using DDW instead of Chitosan aqueous solution. In this procedure, polymerization was allowed to continue for approximately 10 minutes. After adding each substance to the test tube, the reaction mixture was shaken vigorously. Finally, sodium bicarbonate was added very quickly to the solution and mixed with a spatula. Synthesized SPHCs were removed with a forceps, allowed to dry in oven at 60°C for 48 hours, and cut into pieces of required size. The SPHC was submerged in hexane overnight. This treatment dehydrated the SPHCs rapidly as well as provided drying. Thereafter, the SPHCs were removed with the forceps and put in an oven at 60°C for 48 hours, to ensure that the SPHCs had been dried completely. These SPHCs were stored in an airtight container until further use.

Scanning electron microscopy analysis {#sec2-3}
-------------------------------------

The dried SPHCs were cut to expose their inner structure and used for scanning electron microscopy (SEM) studies. The morphology and porous structure of the SPHC was examined using ESEM EDAX XL-30 Scanning Electron Microscope (Philips, Netherlands), with an operating voltage of 30 kV.

Measurement of density, porosity, swelling parameters, and mechanical strength {#sec2-4}
------------------------------------------------------------------------------

For density measurement, the solvent displacement method was used.\[[@ref36]\] Dried SPHC was used for density measurement, which actually showed the apparent density of the SPHC. A piece of SPHC was taken and weighed in order to determine the mass of the piece. A piece of the polymer was immersed in a predetermined volume of hexane in a graduated cylinder, and the increase in the hexane volume was measured as the volume of the polymer. The density was calculated from equation 1:

where, V~*SPHC*~ is the volume of solvent displaced by SPHC and *M~SPHC~* is the mass of the SPHC.

For porosity measurement, the dried SPHC was immersed in hexane overnight and weighed after the excess hexane on the surface was blotted. The porosity was calculated from equation 2:

where, V~*P*~ (= V~*T*~ - V~*SPHC*~) is the pore volume of SPHC and V~*T*~ is the total volume of SPHC. Total volume of SPHC can be measured from its dimensions, as it is cylindrical in shape.

The equilibrium swelling ratio can be calculated from equation 3:

where, Q is the equilibrium swelling ratio, *M~s~* is the mass in the swollen state, and *M~d~* is the mass in the dried state. At the beginning of each experiment, the dried gel was measured gravimetrically to obtain *M~d~* and then it was immersed in an excess of medium, for swelling. At various time intervals, the hydrogel was removed from the medium and weighed when excessive medium on the surface was blotted to determine *M~s~*.\[[@ref24]\]

The penetration pressure of the SPHC was measured using a bench comparator as described by Chen *et al*., with modifications.\[[@ref34]\] The fully swollen hydrogel was put longitudinally under the lower touch and weights were successively applied to the upper touch until the polymer completely fractured. The compressive force could be read from the gauge, and the penetration pressure\[[@ref35]\] could be calculated from equation 4:

where, *PP* is the penetration pressure, *F~u~* is the ultimate compressive force at complete breakage of the polymer and S is the area of lower touch.

Preparation of the SPHC-based drug delivery system (SPHC-DDS) {#sec2-5}
-------------------------------------------------------------

The SPHC-DDS was prepared as a core inside the delivery system (shuttle system) as reported by Dorkoosh *et al*.,\[[@ref43]\] with modifications, as shown in [Figure 1](#F1){ref-type="fig"}, which consisted of two components, (a) conveyor system made of SPHC; (b) core containing a mixture of R-HCl and the polymer. In order to prepare the conveyor system, a hole was made at a certain depth in the prepared SPHC, which was used as the body. The SPHC was allowed to swell in DDW to its maximum and then the excess water from the surface was blotted. A hole of the desired size, which could accommodate core formulation after drying, was made at the center of the SPHC with the help of a borer. The swollen SPHC was then dried in an oven at a temperature below 50°C. To make the core component, R-HCl equivalent to 300 mg of Ranitidine was thoroughly mixed with the release retardant polymers, as shown in [Table 1](#T1){ref-type="table"}. After preliminary studies (data not shown) the selected amounts of HPMC, Carbopol, EC, Chitosan, and NaCMC, as a release retardant polymer in core formulation, were 150 mg, 100 mg, 150 mg, 150 mg, and 150 mg, respectively. The mixture was sieved through 80\# sieve and used as the core formulation. The core component was filled in the hole, prepared in the SPHC. The hole was closed securely with a piece of SPHC, used as a cap, with the help of biodegradable glue. Here a piece of SPHC with the same composition as the body was used as a cap, instead of SPH as reported by Dorkoosh *et al*.\[[@ref43]\] The prepared SPHC-DDS was placed in a hard gelatin capsule (size 000) before *in vitro* drug release studies. Although the preparation of SPHC-DDS was a bit complex, it provided another aspect of the floating drug delivery system.

![Schematic diagram of SPHC-DDS (Core inside the shuttle system)](JPBS-2-124-g005){#F1}

###### 

CORE composition of Chitosan SPHC-DDSs

![](JPBS-2-124-g006)

Floating behavior of SPHC-DDSs {#sec2-6}
------------------------------

The SPHC-DDS was placed in a 100 ml beaker containing SGF.\[[@ref40]\] The time required for SPHC-DDS to rise to the surface and float was taken as the floating lag time. The total time period for which SPHC-DDS remained buoyant was considered as the total floating time.

*In vitro* drug release studies {#sec2-7}
-------------------------------

The release rate of R-HCl from SPHC-DDS (*n* = 3) was determined by using the USP XXIV dissolution testing apparatus II (dissolution tester model TDT-08 L, Electrolab, India). The drug release test was performed using 900 ml SGF, at 37 ± 0.5°C and 75 rpm.\[[@ref44]\] Volumes of 10 ml were withdrawn at predetermined interval times (hourly) for 18 hours from the dissolution medium and were replaced immediately with fresh medium. The samples were passed through a 0.45 *μ*m membrane filter and diluted (if needed) to a suitable concentration, with SGF. The absorbance of these solutions was measured at 314 nm by using a UV-1700 UV / VIS double beam spectrophotometer (Shimadzu, Japan). The cumulative percentage of drug release was calculated using an equation obtained from a standard curve.

The *in vitro* drug release data of all the batches were analyzed by fitting them to different kinetic models, as shown in [Table 2](#T2){ref-type="table"},\[[@ref45]--[@ref54]\] in order to evaluate the release mechanism of the drug from SPHCs.

###### 

Mathematical models used to ascertain drug release\[[@ref45]--[@ref54]\]

![](JPBS-2-124-g007)

Stability studies {#sec2-8}
-----------------

The prepared batches were kept in airtight containers and stored in a stability chamber (TH-90S, Thermolab, India) at 40°C / 75%RH for three months. Results of the *in vitro* drug release studies obtained after three months were compared with the data obtained at the time of preparation. The similarity factor (*f*~2~) and floating behavior were applied to study the effect of storage. The similarity factor can be calculated using equation 5.

Where, *n* is the number of dissolution time points and *R~j~* and *T~j~* are the dissolved percent of the reference product and test product at each time point *j*, respectively.

Results and Discussion {#sec1-2}
======================

SPHC synthesis {#sec2-9}
--------------

In the synthesis procedure of SPHC, AA and AM are the monomers. BIS is used as a cross-linker, and span 80 is used as a foam stabilizer, which is formed by carbon dioxide originating from sodium bicarbonate. Here span 80 has been used instead of Pluronic F127 as reported by Dorkoosh *et al*.\[[@ref55]\] Span 80 does not contribute to the chemical structure of the polymer, but is very important as a surface-active agent, to create a highly porous polymer structure. APS is used as a polymerization initiator and TEMED as a catalyst. The pH of the AA monomer solution is an important factor that influences the synthesis of the SPHCs. At pH 5.0, SPHCs with well-distributed pores are produced because of the stability and the proper formation rate of the foam.

Synthesis of homogeneous SPHC with a number of pores depended on the amount of Chitosan present. Only when the amount of Chitosan was less than 47.06% of the SPH, homogeneous hydrogels with a number of interconnected pores could be obtained. When the amount was increased to above 47.06% (data not shown), the hydrogel was nonhomogeneous, in that, only a few pores were maintained. As a thickening agent, Chitosan enhanced the viscosity of the stock solution, which efficiently prevented bubbles from escaping from the solution and the residual gas bubbles were able to form interconnected channels. Good solubility of the Chitosan solution at pH values lower than 6,\[[@ref56]\] it could be readily blended with the stock solution and well distributed in the SPH, yielding a homogeneous SPHC.

Scanning electron microscopy analysis {#sec2-10}
-------------------------------------

[Figure 2](#F2){ref-type="fig"} shows the SEM pictures of SPHC and SPH. Both SPH and SPHC possessed a numbers of pores, indicating that the formation of a hydrogel would not destroy the superporous structure. White fibers on the peripheries of the inner pores were observed in SPHC, although not in SPH, which were primarily determined to be the Chitosan molecules. The fully swollen SPH was transparent in DDW and lots of bubbles could be seen within the hydrogel. By comparison, white fibers could be observed in the swollen SPHC, which appeared as a netlike distribution. Such differences indicated that the white fibers could be the Chitosan molecules and they were well distributed in the polymer to form a three-dimensional network, which primarily confirmed the formation of SPHC.

![SEM image of SPH; magnification 1 mm](JPBS-2-124-g009){#F2}

![SEM image of SPHC; magnification 1 mm](JPBS-2-124-g010){#F3}

Measurement of density, porosity, swelling parameters, and mechanical strength {#sec2-11}
------------------------------------------------------------------------------

Density, porosity, swelling parameters and mechanical strength of SPH and SPHC are shown in [Table 3](#T3){ref-type="table"}. Apparent density increased, while the porosity of SPHC decreased in the presence of Chitosan. Chitosan prevented the bubbles from escaping from the solution mixture as well as decreased the pore size of SPHC, due to the accumulation of Chitosan at the periphery of the pores. At higher concentration (data not shown) excessive water was introduced into the system, leading to the collapse of some of the bubbles and a corresponding significantly lower porosity than SPH.

###### 

Parameters comparison of SPH and SPHC

![](JPBS-2-124-g011)

An increase in Chitosan concentration led to slower swelling and decreased the equilibrium swelling ratio of the SPHCs. Through entanglement with the cross-linked Chitosan network, the flexibility of the polymeric chains was greatly restricted. Hydrogen bonds between Chitosan and poly (AM-co-AA) reduced the ability of the polymer to form hydrogen bonds with water molecules, thus limiting its water absorption. Therefore, a dense Chitosan network would further restrict the swelling of the polymer. However, compared to nonporous hydrogels, SPHCs still possessed a significantly faster swelling rate and larger equilibrium swelling ratios, owing to their porous structures.

An SPHC should be able to withstand the pressure expected in the stomach during repeated gastric contractions, especially the housekeeper waves. SPHC when swollen in DDW showed mechanical strength that could withstand the pressure during gastric contraction, but when compared to that in SGF it was less. SPHC showed very good penetration pressure, more than 500 cm water, when swollen in SGF. The maximum pressure during gastric contraction was reported to be in the range of 50 to 130 cm water.\[[@ref57][@ref58]\] An increase in the amount of Chitosan helped bring about a denser Chitosan network and a smaller equilibrium swelling ratio, thus enhancing the elasticity of the polymer.

Floating behavior of SPHC-DDSs {#sec2-12}
------------------------------

The highly porous structure of the SPHC-DDS provides a density that is lower than the density of the release medium. In contrast to the most conventional floating systems including the gas-generating ones, these systems floated immediately upon contact with the release medium, with no lag-time in their floating behavior, because low density was provided from the beginning (*t* = 0). It was possible to achieve proper *in vitro* floating behavior for more than 18 hours, in these systems.

*In vitro* drug release studies {#sec2-13}
-------------------------------

All the formulations were found to be swollen, floating, and retained their physical integrity till the end of the 17-hour drug release study. Batches CH2 to CH6 were formulated to study the effect of various release retardant polymers on the drug release from SPHCs. Batch CH1 was formulated to check the drug release in the absence of a polymer.

The drug release data of the batches was fitted to the zero-order, first-order, Higuchi, Hixson-Crowell, Korsmeyer-Peppas, Weibull, and Hopfenberg models. The *in vitro* drug release profile of R-HCl in SGF from SPHCs is shown in [Figure 3](#F4){ref-type="fig"}.

![*In vitro* drug release profile of R-HCl from SPHCs in SGF (Mean, n = 3)](JPBS-2-124-g012){#F4}

The zero-order rate describes systems where the drug release rate is independent of its concentration. The first-order describes the release from systems where the release rate is concentration-dependent. Higuchi\'s model describes the release of drugs from an insoluble matrix as a square root of a time-dependent process, based on Fickian diffusion.\[[@ref48][@ref49]\] The applicability of the formulation to the Hixson-Crowell cube root law equation might indicate that there is a change in the surface area and diameter of the SPHCs, with progressive dissolution of the formulation as a function of time. Korsmeyer-Peppas model is expected to be valid only up to \~60% cumulative drug release,\[[@ref51]\] therefore, the data for analysis are restricted to that range. Korsmeyer-Peppas plots are shown in [Figure 4](#F5){ref-type="fig"}. Weibull plots can describe the drug release curve in terms of applicable parameters. The shape parameter, b, characterizes the curve as either exponential (β = 1), S-shaped with upward curvature followed by a turning point (β \> 1), or as one with a steeper initial slope than is consistent with the exponential (β \< 1).\[[@ref52]\] The Hopfenberg model is applied to ascertain the release of the drug from surface-eroding devices, with a cylinder displaying heterogeneous erosion.

![Korsmeyer-Peppas plots for SPHC-DDSs](JPBS-2-124-g013){#F5}

The curve fitting and plotting was performed on Excel (Microsoft Software Inc., USA) and *GraphPad Prism*^®^ version 5.02 (GraphPad Software Inc., USA). Linearization of drug release profiles, using the equations in [Table 2](#T2){ref-type="table"}, was used to characterize the differences found among all batches. The values for the release rate constants, the correlation coefficients (r^2^), and the release exponent (*n*) were considered. The correlation coefficient (r^2^) was used as an indication of the best fit, for each of the models considered. The release constant was calculated from the slope of the appropriate plots, the regression coefficient for individual batches was determined as shown in [Table 4](#T4){ref-type="table"}. The average r^2^ of all the batches was used to select the best fit model and this model would indicate the release mechanism of the drug especially from SPHC-DDSs.

###### 

Linearization of R-HCl release from SPHC-DDSs

![](JPBS-2-124-g014)

SPHC-DDSs were different from conventional oral dosage forms such as tablets and capsules. It was found that the in vitro drug release of SPHC was best explained by the Korsmeyer-Peppas model, as the plots showed the highest linearity (r^2^ = 0.9964), followed by Hixson-Crowell (r^2^ = 0.9723), Hopfenberg (r^2^ = 0.9681), Higuchi (r^2^ = 0.9624), and Weibull (r^2^ = 0.9584). There was less probability of zero-order and first-order release. The magnitude of the exponent *n* in Korsmeyer-Peppas' equation indicated that the release mechanism was Fickian diffusion, case II transport, or anomalous transport. In the present study (cylindrical shape) the limits considered were *n* = 0.45 (indicated a classical Fickian diffusion-controlled drug release) and *n* = 0.89 (indicated a case II relaxational release transport: polymer relaxation controls drug delivery). Values of *n* between 0.45 and 0.89 could be regarded as indicators of both phenomena (transport corresponding to coupled drug diffusion in the hydrated matrix and polymer relaxation), commonly called anomalous non-Fickian transport. Values of *n* greater than 0.89 indicated super case II transport, wherein, a pronounced acceleration in solute release by a film occurred toward the latter stages of release experiments, resulting in a more rapid relaxation-controlled transport.\[[@ref59]\] In our studies the values of *n* ranged between 0.47 ± 0.02 and 0.66 ± 0.02, which appeared to indicate a coupling of the diffusion and polymer relaxation mechanisms, anomalous non-Fickian transport, and might indicate that the drug release from SPHC could be controlled by more than one process.

The prepared SPHC-DDS must be safe as it is retained in the stomach for a long period of time. Dorkoosh *et al*.,\[[@ref60]\] and Risbud and Bhonde\[[@ref61]\] have shown the feasibility and safety of similar drug delivery systems. Cytotoxicity assays of the SPH interpenetrating network on RBL-2H3 and Caco-2 cells cause minimal damage to cell viability, lysosomal activity, and metabolic activity, as reported by Yin *et al*.\[[@ref62]\] Therefore, the SPHC-DDS must be preliminarily considered to be biocompatible and may be safe.

Stability studies {#sec2-14}
-----------------

The stability studies showed that there were no significant changes observed in the *in vitro* drug release studies after three months. Batch CH1 to CH6 were considered as reference for the respective batches (put on stability studies) for similarity factor (*f*~2~) calculation. After three months of applied stability conditions, all the batches were seen to be similar to the reference batches, with the exception of Batch CH1. These batches floated immediately upon contact with the release medium, with no lag-times in floating behavior. [Table 5](#T5){ref-type="table"} shows *f*~2~ values for batches put on stability studies. Although SPHC-DDSs were found to be stable for a period of three months at 40°C / 75%RH, the *f*~2~ values were not close to 100, which indicated that some changes in the delivery systems might have occurred during storage. Due to the porous structure of the SPHC-DDS, the drug and / or polymer could have been affected at a constant temperature of 40°C.

###### 

*f*~2~ values for batches put on stability studies

![](JPBS-2-124-g015)

Conclusion {#sec1-3}
==========

This study discusses the preparation of a floating stomach-specific drug delivery system of R-HCl. SPHC possesses better characteristics than SPH, especially for sustained release drug delivery systems. The mechanical stability of SPHC in SGF is significantly improved and depends on the Chitosan content. SPHC-DDS is mechanically stable, low dense, has good swelling capacity, and is pH-dependant. The *in vitro* drug release from SPHC is best explained by the Korsmeyer-Peppas model. The Korsmeyer-Peppas plots have indicated anomalous non-Fickian transport, and hence, the drug release is controlled by more than one process. SPHC-DDSs are found to be stable for a period of three months at 40°C / 75%RH. A sustained release R-HCl drug delivery system has been prepared successfully using a SPHC, with Chitosan as a composite material.
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